ArticleUrolithiasis2015
Dyslipidemia is associated with an increased risk of nephrolithiasis.
Article in Urolithiasis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- The causal relationship between 179 lipid species and urolithiasis: a bidirectional and multivariable Mendelian randomization study combined with meta-analysis.Lipids in health and disease · 2025Pooled it
- Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies.European journal of epidemiology · 2018Pooled it
- A randomized clinical trial evaluating the short-term results of ureteral stent encrustation in urolithiasis patients undergoing ureteroscopy: micro-computed tomography evaluation.Scientific reports · 2021Trial
- Effects of short-term atorvastatin use in patients with calcium stones: A randomized placebo-controlled clinical trial.Investigative and clinical urology · 2019Trial
- Probucol inhibits palmitic acid-mediated renal calcium oxalate stone formation by targeting KLF5-PPARγ axis-mediated lipotoxicity.Journal of pharmaceutical analysis · 2026Article
- Association between risk-weighted apolipoprotein B and prevalent kidney stones: a retrospective case-control study.Frontiers in medicine · 2026Article
- Article
- Associations of metabolic syndrome and its components with complex renal calculi and stone composition: a cross-sectional study.European journal of medical research · 2025Article
- A study on the relationship between the weight-adjusted waist index and kidney stone prevalence mediated by diabetes: data from NHANES 2007-2018.Scientific reports · 2025Article
- Article
- Association between the atherogenic index of plasma and kidney stones: a nationally representative study.BMC urology · 2024Article
- The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stones: a cross-sectional study.Lipids in health and disease · 2024Article
- Dysregulated palmitic acid metabolism promotes the formation of renal calcium-oxalate stones through ferroptosis induced by polyunsaturated fatty acids/phosphatidic acid.Cellular and molecular life sciences : CMLS · 2024Article
- The association of dyslipidemia with kidney stone: result from the NHANES 2007-2020.International urology and nephrology · 2024Article
- Ae index is an independent predictor of kidney stone recurrence in overweight and obese patients.BMC urology · 2023Article
- Article
- TheFrontiers in endocrinology · 2023Article
- Serum and urine uric acid level may have different predictive value for urinary stone composition: a retrospective cohort study of 718 patients in Chinese population.International urology and nephrology · 2022Article
- Dyslipidemia Increases the Risk of Incident Kidney Stone Disease in a Large Taiwanese Population Follow-Up Study.Nutrients · 2022Article
- Plasma oxalic acid and cardiovascular risk in end-stage renal disease patients: a prospective, observational cohort pilot study.The Korean journal of internal medicine · 2022Observational
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
The pathophysiology of nephrolithiasis is multifactorial. Obesity, diabetes mellitus and hypertension are implicated in its formation. Dyslipidemia (DLD) recently has received attention as well. Congruent with a vascular etiology in stone formation, DLD theoretically would predispose patients to nephrolithiasis. We investigated a possible association of DLD with nephrolithiasis. A random cohort of 60,000 patients was established by collecting the first 5,000 patient charts per month in the year 2000. After excluding pediatric patients, a retrospective study was performed by reviewing age, sex, comorbidities, and last patient follow-up. Median lipid laboratory levels also were reviewed. Descriptive statistics were performed as well as Cox proportional-hazards regression analysis, and univariate and multivariate analyses. 52,184 (22,717 women/29,467 men) patient charts were reviewed. The average age was 31.0 ± 15.2 years. On univariate analysis, DLD was associated with nephrolithiasis with a hazard ratio (HR) of 2.2 [Confidence Interval (CI), 1.9-2.5; p < 0.001] and on multivariate analysis HR = 1.2 (1.0-1.5; p = 0.033). Low-density lipoprotein and triglycerides had no association with stone disease. Patients with high-density lipoprotein (HDL) values <45 for men and <60 for women had an HR of 1.4 (1.1-1.7, 95% CI, p = 0.003) on univariate analysis and on multivariate analysis; HR = 1.27 (1.03-1.56; p = 0.024) for nephrolithiasis. DLD was associated with an increased risk of stone disease though the only specific lipid panel associated with lower nephrolithiasis was HDL. Clinicians should consider obtaining lipid levels with the intent that treatment could potentially not only mitigate atherosclerotic disease but also decrease nephrolithiasis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.